April 22, 2025 1:30–1:50 PM
Strategy 1
Annate Bitherapeutics is developing a therapeutic platform that utilizes ApoL1, a naturally occurring component of the innate immune system. It is guided by our proprietary bispecific antibodies to become selectively lethal to cancer cells. This innovative mechanism complements existing therapies, with strong efficacy in multiple myeloma and promising preclinical results in pancreatic cancer models, demonstrating the platform’s broad potential across multiple tumor types.
Sponsors
